Neuropathic pain - The case for opioid therapy

被引:4
|
作者
Allen, Stephen C. [1 ]
机构
[1] Royal Berkshire Hosp, Reading RG6 5RN, Berks, England
关键词
neuropathic pain; opioids; rational polypharmacy; oxycodone;
D O I
10.1159/000143224
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For many patients, neuropathic pain (NeP) is arguably more difficult to control than nociceptive or 'normal' pain. We also now recognise the great burden that NeP has on the lives of patients - it is not only a matter of treating pain in isolation, but managing all of the issues that affect the patient's quality of life. Until relatively recently we have had little understanding of the pathophysiology causing NeP and have relied on the secondary effects of non-analgesic drugs as the mainstays of treatment. Greater understanding of the pathophysiology of NeP has led to more appropriate therapy and an increased use of multiple drug therapy - 'rational polypharmacy'. Traditional opinions concerning the treatment of NeP have been challenged and it is because of this that the use of opioids in NeP has been re-evaluated. Opioids will never replace tricyclic antidepressants and anti-epileptic drugs as first-line therapy for NeP. However, they are now fully established as effective and useful second- or third-line drugs. Many patients in the past have been potentially undertreated as a result of our inertia to use opioids. The case for opioid therapy in NeP has been firmly established. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [21] NEW THERAPY FOR NEUROPATHIC PAIN
    Mizoguchi, Hirokazu
    Watanabe, Chizuko
    Yonezawa, Akihiko
    Sakurada, Shinobu
    ADVANCES IN NEUROPHARMACOLOGY, 2009, 85 : 249 - 260
  • [22] Latent Pain Sensitization unmasks μ-δ opioid heteromer in neuropathic and inflammatory pain
    Inyang, Kufreobong
    George, Sarah
    Laumet, Geoffroy
    JOURNAL OF PAIN, 2021, 22 (05): : 581 - 581
  • [23] Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain
    Meske, Diana S.
    Xie, Jennifer Y.
    Oyarzo, Janice
    Badghisi, Hamid
    Ossipov, Michael H.
    Porreca, Frank
    NEUROSCIENCE LETTERS, 2014, 562 : 91 - 96
  • [24] Physical Functioning and Opioid use in Patients with Neuropathic Pain
    Bostick, Geoff P.
    Toth, Cory
    Carr, Eloise C. J.
    Stitt, Larry W.
    Morley-Forster, Patricia
    Clark, Alexander J.
    Lynch, Mary
    Gordon, Allan
    Nathan, Howard
    Smyth, Catherine
    Ware, Mark A.
    Moulin, Dwight E.
    PAIN MEDICINE, 2015, 16 (07) : 1361 - 1368
  • [25] Activity at mGluRs: Modulation of opioid dependence and neuropathic pain
    Fundytus, ME
    Henry, JL
    NEUROPHARMACOLOGY, 1999, 38 (10) : A49 - A49
  • [26] Selective δ opioid receptor agonists for inflammatory and neuropathic pain
    Dondio, G
    Ronzoni, S
    Farina, C
    Graziani, D
    Parini, C
    Petrillo, P
    Giardina, GAM
    FARMACO, 2001, 56 (1-2): : 117 - 119
  • [27] Neuropathic pain is enhanced in δ-opioid receptor knockout mice
    Nadal, X
    Baños, JE
    Kieffer, BL
    Maldonado, R
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (03) : 830 - 834
  • [28] The antinociceptive effect of opioid analgesics in neuropathic cancer pain
    Sugawara, Ryou
    Mizoguchi, Hirokazu
    Watanabe, Chizuko
    Yonezawa, Akihiko
    Kanno, Syu-ichi
    Ishikawa, Masaaki
    Nagase, Hiroshi
    Sakurada, Shinobu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 154P - 154P
  • [29] Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain
    Caraceni, A
    Zecca, E
    Martini, C
    De Conno, F
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 17 (06) : 441 - 445
  • [30] NEUROIMMUNE INTERACTIONS IN NEUROPATHIC PAIN FOCUS ON OPIOID SYSTEMS
    Przewlocka, Barbara
    NEUROPEPTIDES, 2010, 44 (06) : 530 - 531